29 - Breaking Ground: ID Clinical Trials

Moderator(s)

• 

  Thomas Holland, MD

  Associate Professor, Department of Medicine, Division of Infectious Diseases
  Duke University Medical Center
  Durham, NC, United States
• 

  Cesar Arias, MD, MSc, PhD (he/him/his)

  Professor and Chief
  Houston Methodist and Weill Cornell Medical College
  Houston, TX, United States

Presentations:

• 10:30 AM – 10:45 AM US PT

  Comparative Evaluation of Low Versus High Doses of Rifampin for the Treatment of Staphylococcal Bone and Joint Infections: an open-label, randomized, controlled non-inferiority trial (EVRIOS)
  

  Presenting Author: Cedric Arvieux, MD (he/him/his) – CHU de Rennes

  Co-Author: Jean-Marc Chapplain, MD – CHU de Rennes

  Co-Author: Anne Jolivet-Gougeon, PharmD, PHD – CHU RENNES

  Co-Author: Jean-François Morcet, n/a – CHU RENNES

  Co-Author: Violaine Benoit, n/a – CHU RENNES

  Co-Author: Cecile Lefeuvre, n/a – CHU RENNES

  Co-Author: Florian Lemaitre, PharmD – CHU RENNES

  Co-Author: Nathalie Asseray, MD – CHU DE NANTES - HOTEL DIEU

  Co-Author: Aurélien Lorleac'h, MD – CH BRETAGNE SUD

  Co-Author: Frederic Antoine Dauchy, MD – CHU BORDEAUX

  Co-Author: Thomas Guimard, MD – CHD VENDEE

  Co-Author: Gwenael Lemoal, MD – CHU POITIERS

  Co-Author: Valérie Gaborieau, MD – CH PAU

  Co-Author: Grégory Corvaisier, MD – CH VANNES

  Co-Author: Rodolphe Buzele, MD – CH SAINT-BRIEUC

  Co-Author: Pierre Delobel, MD – CHU TOULOUSE

  Co-Author: Fabien Fily, MD – CH SAINT-MALO

  Co-Author: Pierre Abgueguen, MD – CHU ANGERS

  Co-Author: Jocelyn Michon, MD – CHU DE CAEN

  Co-Author: Florence Suy, MD – Hôpital Privé Jean Mermoz - Clinique du Parc / LYON

  Co-Author: Anne Méheut, n/a – CHU RENNES

  Co-Author: marie Gheno, n/a – CHU DE RENNES

  Co-Author: Maja Ratajczak, PharmD, PHD – CHU de Rennes

  Co-Author: Anaïs Grèves, n/a – CHU BREST

  Co-Author: Céline Thomas, n/a – CHU POITIERS

  Co-Author: Mustapha Ahmim, n/a – CHU DE RENNES

  Co-Author: Romain Muraz, n/a – CHU DE RENNES

  Co-Author: Bellec Laurent, MD – CH de Pontivy

  Co-Author: Cailleaux Marine, MD – CHU de Rennes

  Co-Author: Lecomte Raphael, MD – CHU de Nantes

  Co-Author: Séverine Ansart, MD, PHD – CHU DE BREST

  Co-Author: Louis Bernard, MD/PHD – CHU TOURS
• 10:45 AM – 11:00 AM US PT

  Predictors of Undetectable HDV RNA 48 weeks after completion of finite treatment with Bulevirtide and Pegylated-Interferon Alpha 2a
  

  Presenting Author: Pavel Bogomolov, MD, Ph.D (he/him/his) – M.F. Vladimirsky Moscow Regional Research and Clinical Institute, Moscow, Russian Federation

  Co-Author: Tatyana Stepanova, MD – LLC Clinic of Modern Medicine, Moscow, Russian Federation

  Co-Author: Viacheslav Morozov, MD, PhD – LLC Medical Company Hepatolog, Samara, Russian Federation

  Co-Author: Tarik Asselah, PhD – Hopital Beaujob APHP, Universite de Paris, INSERM

  Co-Author: Fabien Zoulim, MD, PhD – Hospital Croix Rousse

  Co-Author: Adrian Streinu-Cercel, PhD – Matei Bals National Institute of Infectious Diseases, Bucharest, Romania; "Carol Davila" University of Medicine and Pharmacy

  Co-Author: George Sebastian Gherlan, MD, PhD – "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania; Dr. Victor Babes Foundation

  Co-Author: Olga Sagalova, MD, PhD – South Ural State Medical University, Chelyabinsk, Russian Federation

  Co-Author: Dana Tedesco, PhD – Gilead Sciences, Inc.

  Co-Author: Renee-Claude Mercier, PharmD – Gilead Sciences, Inc.

  Co-Author: Lei Ye, PhD – Gilead Sciences, Inc.

  Co-Author: Dmitry Manuilov, MD – Gilead Sciences, Inc.

  Co-Author: Audrey Lau, MD, PhD – Gilead Sciences, Inc.

  Co-Author: Marc Bourliere, MD, PhD – Hopital Saint Joseph

  Co-Author: Vladimir Chulanov, MD, PhD – Sechenov University
• 11:00 AM – 11:15 AM US PT

  Improving Traditional Registrational Trial Endpoints: Development and Application of a Desirability of Outcome Ranking (DOOR) Endpoint for Acute Bacterial Skin and Skin-Structure Infections
  

  Presenting Author: Jessica Howard-Anderson, MD, MSc (she/her/hers) – Emory University

  Co-Author: Toshimitsu Hamasaki, PhD – The George Washington University

  Co-Author: Lizhao Ge, MAS – George Washington University

  Co-Author: Deborah Collyar, B.Sci – Patient Advocates In Research (PAIR)

  Co-Author: Sumathi Nambiar, MD MPH – Johnson and Johnson

  Co-Author: Carol Hill, PhD – Duke Clinical Research Institute

  Co-Author: Holly S. Geres, BS – Duke Clinical Research Institute

  Co-Author: Sara E. Cosgrove, MD, MS – Johns Hopkins School of Medicine

  Co-Author: Thomas L. Holland, MD – Duke University Medical Center

  Co-Author: Sarah B. Doernberg, MD, MAS (she/her/hers) – University of California, San Francisco

  Co-Author: Henry Chambers, MD – University of California San Francisco

  Co-Author: Vance G. Fowler, MD, MHS – Duke University Medical Center

  Co-Author: Scott R. Evans, PhD, M.S. (he/him/his) – Milken Institute School of Public Health

  Co-Author: Helen Boucher, MD (she/her/hers) – Tufts University School of Medicine
• 11:15 AM – 11:30 AM US PT

  Improved Survival with Dual Immunomodulator Treatment of ARDS by blocking C5a and IL-6 Activity: Subanalysis from the PANAMO Study in Critically Ill COVID-19 Patients
  

  Presenting Author: Roy F. Chemaly, MD/MPH (he/him/his) – University of Texas MD Anderson Cancer Center

  Co-Author: Alexander Vlaar, MD, PhD – Amsterdam UMC

  Co-Author: Endry H.T. Lim, MD, PhD – Amsterdam UMC

  Co-Author: Bruce P. Burnett, PhD (he/him/his) – InflaRx GmbH, InflaRx Pharmaceuticals, Inc.

  Co-Author: Camilla Chong, MD – InflaRx GmbH

  Co-Author: simon Rückinger, PhD – Metranomia Clinical Research GmbH

  Co-Author: Robert Zerbib, MSc – InflaRx GmbH

  Co-Author: Raymond M. Panas, PhD – InflaRx Pharmaceuticals, Inc.

  Co-Author: Renfeng Guo, MD – InflaRx GmbH

  Co-Author: Niels Riedemann, MD, PhD – InflaRx GmbH

  Co-Author: Diederik van de Beek, MD, PhD – Amsterdam UMC
• 11:30 AM – 11:45 AM US PT

  The Platform Trial In COVID-19 Priming and BOOsting (PICOBOO): the immunogenicity, reactogenicity, and safety of different COVID-19 vaccinations administered as a second booster (fourth dose) in AZD1222 primed individuals aged 50-< 70 years old.
  

  Presenting Author: Charlie McLeod, PhD, MBBS (Hons), FRACP, DTMH, DCH – Telethon Kids Institute

  Co-Author: Michael Dymock, BSc – Telethon Kids Institute

  Co-Author: Katie Flanagan, PhD – Launceston General Hospital

  Co-Author: Magdalena Plebanski, PhD – Royal Melbourne Institute of Technology University (RMIT)

  Co-Author: Helen Marshall, MD – University of Adelaide

  Co-Author: Marie Estcourt, PhD – University of Sydney

  Co-Author: Ushma Wadia, MBBS – Telethon Kids Institute

  Co-Author: Christian Tjiam, PhD – Telethon Kids Institute

  Co-Author: Christopher C. Blyth, MBBS(Hons), DCH, FRACP, FRCPA, PhD (he/him/his) – Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute

  Co-Author: Kanta Subbarao, MBBS, MPH – WHO Collaborating Centre for Reference and Research on Influenza, Melbourne, Australia

  Co-Author: Francesca Mordant, PhD – Doherty Institute

  Co-Author: Suellen Nicholson, BSci – University of Melbourne

  Co-Author: Saul N. Faust, FRCPCH PhD (he/him/his) – University of Southampton and University Hospital Southampton NHS Foundation Trust

  Co-Author: Ruth Thornton, PhD – Telethon Kids Institute

  Co-Author: Anne McKenzie, Consumer Expert – Telethon Kids Institute

  Co-Author: Julie Marsh, PhD – Telethon Kids Institute

  Co-Author: Thomas L. Snelling, BMBS, DTMH, GDipClinEpid, PhD, FRACP – University of Sydney

  Co-Author: Peter Richmond, MBBS – University of Western Australia School of Medicine, Perth’s Children Hospital